At some point in the future, an individual’s genome will be a foundational part of their medical record. Driving towards precision medicine involves increasingly comprehensive sequencing and arrays, access to standardized testing, integration into systems used by health care providers to manage patients, and building evidence that genomic information has clinical utility and can be used to improve outcomes. Sustainable incorporation of genomics into routine care requires efficient testing, readily accessible genomic data and decision support, and data aggregation that can assess patient outcomes. In this session, various stakeholders, including both healthcare (large, integrated healthcare systems), healthcare information technology, and insurance providers, will share their perspectives on current approaches and the challenges they observe on achieving this goal.
Dr. Phil G. Febbo is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice. Dr. Febbo has a successful track record of translational research, clinical excellence, and for embedding molecular insights into clinical care. Immediately before joining Illumina, Dr. Febbo served as CMO of Genomic Health for five years where he drove the company’s medical strategy, was accountable for the team management and development of evidence supporting GHI’s proprietary tests and engaged with the payer community to drive reimbursement. Prior to his five years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. Dr. Febbo currently serves on the board of the American College of Medical Genetics and Genomics Foundation.
Dr. Newcomer focuses his time on innovations that improve the care delivery and affordability of cancer care and genomics. He is a medical oncologist who practiced for ten years. He then spent the majority of his career with UnitedHealth Group where he served as the Chief Medical Officer for 10 years followed by an additional 14 years dedicated to oncology and genetics. During that period he launched the first oncology value based contract and the first commercial cancer database with claims and clinical data. Dr. Newcomer chaired the board of directors at Park Nicollet Clinic, a 1000+ physician and 400 hospital bed integrated delivery provider In Minneapolis. He is currently a director at Myriad Genetics, Cellworks, and Intervention Insights.
Anthony (Tony) Gregg, joined Baylor University Medical Center (Dallas) as Chief, Department of Obstetrics and Gynecology, and Chief, of Maternal-Fetal Medicine in April 2018. He received his medical degree from Loyola University Stritch School of Medicine and did his residency at Loyola Foster McGaw Hospital (Chicago). He went on to complete a maternal-fetal medicine fellowship at the University of Iowa Hospitals and Clinics (Iowa City) and followed this with a fellowship in clinical genetics at Baylor College of Medicine (Houston). Dr Gregg earned his MBA at the University of Florida’s Warrington College of Business. Tony is certified by the American Board of Obstetrics and Gynecology and the American Board of Medical Genetics and Genomics. He is Past-Treasurer and Past –President of the Perinatal Research Society. He is a Past-Chair of the American College of Obstetricians and Gynecologists Committee on Genetics. Tony is the 13th President of the America College of Medical Genetics and Genomics.